Vivos Therapeutics shares fall 1.35% intraday as AbbVie completes acquisition of Capstan Therapeutics.

martes, 19 de agosto de 2025, 11:22 am ET1 min de lectura
VVOS--
Vivos Therapeutics, Inc. declined 1.35% in intraday trading. The recent news events do not directly relate to Vivos Therapeutics, Inc. and therefore do not provide a clear cause for the stock's decline.

Vivos Therapeutics shares fall 1.35% intraday as AbbVie completes acquisition of Capstan Therapeutics.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios